Drug intelligence / Profile preview

JRD-018

Development stage: Unknown
Lead developer: Jingrui Pharmaceutical
Modality: Small Molecules

Overview

JRD-018 is a small molecule drug developed as a BET (Bromodomain and extra-terminal domain) inhibitor. It is designed to inhibit the expression of c-Myc, a classic oncogene, thereby inhibiting tumor growth. The primary indication for JRD-018 is advanced cancer. The drug was initially developed by Jingrui Pharmaceutical (Suzhou Co., Ltd.) and has reached IND (Investigational New Drug) approval status in the United States[1][2][5].

Targets

BET (BET family proteins)

Beyond the preview

Go deeper on JRD-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRD-018.

Explore the full profile